ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

NanoString Expands Partnership with Leica Biosystems to Accelerate Spatial Discoveries with Automated Workflow

Fully automated GeoMx RNA workflow reduces hands-on time, allowing users to prepare up to 30 slides in one day with high reproducibility

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of a fully automated GeoMx® RNA protocol on BOND RX research staining systems through an expanded partnership with Leica Biosystems. The new, improved RNA protocol offers whole transcriptome profiling of Formalin-Fixed Paraffin-Embedded (FFPE), fixed frozen, or fresh frozen tissue, ultimately improving reproducibility and throughput, minimizing manual steps, and reducing hands-on time.

“This fully automated protocol not only increased our ability to get more slides done in a week but also increased the quality of the data coming off of our instrument by reducing variability between runs,” said Carlee Hemphill, formerly a lead scientist with Labcorp, a beta site for the automated workflow, now senior manager, Translational and R&D Services, PathAI.

The GeoMx Digital Spatial Profiler (DSP) combines standard immunofluorescence techniques with digital barcoding technology to perform highly multiplexed, spatially resolved multi-omic profiling studies. The BOND RX staining solution offers investigators an open platform to develop customized protocols for immunohistochemistry (IHC) and In Situ Hybridization (ISH) with open reagents and detection options. The new protocol creates a fully automated GeoMx DSP workflow allowing researchers to quickly see the biological complexity of heterogeneous tissues using GeoMx DSP’s combination of tissue morphological context and high-plex, whole transcriptome RNA expression profiling from a single slide.

“We’re excited to have the Leica workflow as part of our spatial biology ecosystem,” said Vice President of Marketing for NanoString, Anna Berdine. “Enabling full automation facilitates translational and multi-sample studies by improving reproducibility and decreasing the hands-on time down to less than one hour, freeing up researchers to focus more of their time on generating insights from their data.”

To learn more about NanoString’s GeoMx Digital Spatial Profiler, visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Visit LeicaBiosystems.com for more information.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,200 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 100 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Leica is a registered trademark of Leica Microsystems IR GmbH and BOND RX is a trademark of Leica Biosystems Melbourne Pty Ltd. in various jurisdictions.

Contacts

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

 

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.